|Various monoclonal antibody-based treatments for breast cancer exist at different stages of development. Present technologies utilize the nude mouse model of breast cancer, which is not a true reflection of what may occur in normal animals in response to such treatments.
Purdue University researchers found the receptor tyrosine kinase EphA2 is over-expressed in breast cancer cells, and therefore, provides a unique target for breast cancer intervention. An immunocompetent mouse model of breast cancer has been developed for evaluating various therapeutic approaches including those involving activation or inhibition of EphA2.
-Improved mouse model of breast cancer
|(No issued patents found)|
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906
Phone: (765) 588-3475
Fax: (765) 463-3486